Data from Figure 3 demonstrates that inhibition of stemness effectively reduced tumorigenicity of EML4-ALK+ NSCLC cells, suggesting that targeting stemness could be a plausible strategy to treat EML4-ALK+ tumor cells. This evidence concerns the gene ALK and non-small cell lung carcinoma.